WD40 repeat domain proteins: a novel target class?
Nature Reviews Drug Discovery 16, 773 (2017).
doi:10.1038/nrd.2017.179
Authors: Matthieu Schapira, Mike Tyers, Maricel Torrent & Cheryl H. Arrowsmith
Antagonism of protein–protein interactions (PPIs) with small molecules is becoming more feasible as a therapeutic approach. Successful PPI inhibitors tend to target proteins containing deep peptide-binding grooves or pockets rather than the more common large, flat protein interaction surfaces. Here, we review one of the (Source: Nature Reviews Drug Discovery)
Source: Nature Reviews Drug Discovery - October 13, 2017 Category: Drugs & Pharmacology Authors: Matthieu Schapira Mike Tyers Maricel Torrent Cheryl H. Arrowsmith Tags: Review Source Type: research
Tau-based therapies in neurodegeneration: opportunities and challenges
Nature Reviews Drug Discovery 16, 863 (2017).
doi:10.1038/nrd.2017.155
Authors: Chuanzhou Li & Jürgen Götz
Aggregates of the microtubule-associated protein tau are a defining feature of several neurodegenerative diseases that are collectively known as tauopathies, and constitute one of the hallmark lesions of Alzheimer disease (AD). Given the lack of efficacy to date of amyloid-β-targeted therapies for AD, interest is (Source: Nature Reviews Drug Discovery)
Source: Nature Reviews Drug Discovery - October 6, 2017 Category: Drugs & Pharmacology Authors: Chuanzhou Li J ü rgen G ö tz Tags: Review Source Type: research
Breaking barriers to novel analgesic drug development
Nature Reviews Drug Discovery 16, 810 (2017).
doi:10.1038/nrd.2017.202
Author: Ajay S. Yekkirala, David P. Roberson, Bruce P. Bean & Clifford J. Woolf
Nature Reviews Drug Discovery16, 545–564 (2017)The compounds APD371,LY2828360, S-777469 and KHK6188 were incorrectly referred to as inhibitors of the cannabinoid receptors CB1 and CB2 in Table 1, when they are cannabinoid receptor agonists. In addition, KHK6188 is (Source: Nature Reviews Drug Discovery)
Source: Nature Reviews Drug Discovery - October 6, 2017 Category: Drugs & Pharmacology Authors: Ajay S. Yekkirala David P. Roberson Bruce P. Bean Clifford J. Woolf Tags: Corrigendum Source Type: research
Emerging therapies for idiopathic pulmonary fibrosis, a progressive age-related disease
Nature Reviews Drug Discovery 16, 755 (2017).
doi:10.1038/nrd.2017.170
Authors: Ana L. Mora, Mauricio Rojas, Annie Pardo & Moises Selman
Idiopathic pulmonary fibrosis (IPF) is a fatal age-associated disease that is characterized by progressive and irreversible scarring of the lung. The pathogenesis of IPF is not completely understood and current therapies are limited to those that reduce the rate of functional decline in patients with (Source: Nature Reviews Drug Discovery)
Source: Nature Reviews Drug Discovery - October 6, 2017 Category: Drugs & Pharmacology Authors: Ana L. Mora Mauricio Rojas Annie Pardo Moises Selman Tags: Review Source Type: research
Market watch: Innovation in the preclinical antibiotic pipeline
Nature Reviews Drug Discovery 16, 744 (2017).
doi:10.1038/nrd.2017.195
Authors: Ursula Theuretzbacher, Miloje Savic, Christine Årdal & Kevin Outterson
Antibiotic resistance is high on the political agenda and improving the antibiotic R&D pipeline is one of the major action points. The Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) supports antibacterial projects through early preclinical development, with a 5-year budget totalling US$455 million (Nat. (Source: Nature Reviews Drug Discovery)
Source: Nature Reviews Drug Discovery - October 6, 2017 Category: Drugs & Pharmacology Authors: Ursula Theuretzbacher Miloje Savic Christine Å rdal Kevin Outterson Tags: News and Analysis Source Type: research
Deubiquitylating enzymes and drug discovery: emerging opportunities
Nature Reviews Drug Discovery 17, 57 (2018).
doi:10.1038/nrd.2017.152
Authors: Jeanine A. Harrigan, Xavier Jacq, Niall M. Martin & Stephen P. Jackson
More than a decade after a Nobel Prize was awarded for the discovery of the ubiquitin–proteasome system and clinical approval of proteasome and ubiquitin E3 ligase inhibitors, first-generation deubiquitylating enzyme (DUB) inhibitors are now approaching clinical trials. However, although our knowledge of the physiological and (Source: Nature Reviews Drug Discovery)
Source: Nature Reviews Drug Discovery - September 29, 2017 Category: Drugs & Pharmacology Authors: Jeanine A. Harrigan Xavier Jacq Niall M. Martin Stephen P. Jackson Tags: Review Source Type: research
Biomarker strategy in lung cancer
This article discsusses how biomarkers will continue to change the market for non-small-cell lung cancer. (Source: Nature Reviews Drug Discovery)
Source: Nature Reviews Drug Discovery - September 29, 2017 Category: Drugs & Pharmacology Authors: Mine Esencay Andrew Watson Kaushiki Mukherjee Delphine Hanicq Steven I. Gubernick Tags: News and Analysis Source Type: research
Host-directed therapies for bacterial and viral infections
Nature Reviews Drug Discovery 17, 35 (2018).
doi:10.1038/nrd.2017.162
Authors: Stefan H. E. Kaufmann, Anca Dorhoi, Richard S. Hotchkiss & Ralf Bartenschlager
Despite the recent increase in the development of antivirals and antibiotics, antimicrobial resistance and the lack of broad-spectrum virus-targeting drugs are still important issues and additional alternative approaches to treat infectious diseases are urgently needed. Host-directed therapy (HDT) is an emerging approach in the field (Source: Nature Reviews Drug Discovery)
Source: Nature Reviews Drug Discovery - September 22, 2017 Category: Drugs & Pharmacology Authors: Stefan H. E. Kaufmann Anca Dorhoi Richard S. Hotchkiss Ralf Bartenschlager Tags: Review Source Type: research
The human microbiome: opportunity or hype?
This article discusses investment in microbiome-based therapeutic approaches and key questions for the field related to the underlying science, clinical development, regulation and business models. (Source: Nature Reviews Drug Discovery)
Source: Nature Reviews Drug Discovery - September 15, 2017 Category: Drugs & Pharmacology Authors: Pedro M. Valencia Magali Richard Jesse Brock Elsy Boglioli Tags: News and Analysis Source Type: research
Flexibility in the FDA approach to orphan drug development
Nature Reviews Drug Discovery 16, 737 (2017).
doi:10.1038/nrd.2017.151
Authors: Nina L. Hunter, Gayatri R. Rao & Rachel E. Sherman
Scientific advances, in combination with government incentives and commercial opportunity, have fuelled strong investment in orphan drugs, resulting in many innovative therapies. Here, we discuss the approach of the FDA to a range of issues that remain crucial to maintaining this momentum, such as the use of the totality of evidence in evaluating orphan drugs. (Source: Nature Reviews Drug Discovery)
Source: Nature Reviews Drug Discovery - September 1, 2017 Category: Drugs & Pharmacology Authors: Nina L. Hunter Gayatri R. Rao Rachel E. Sherman Tags: Comment Source Type: research
Opportunities for therapeutic antibodies directed at G-protein-coupled receptors
Nature Reviews Drug Discovery 16, 661 (2017).
doi:10.1038/nrd.2017.173
Author: Catherine J. Hutchings, Markus Koglin, William C. Olson & Fiona H. Marshall
Nature Reviews Drug Discovery16 (2017)In the article, the clinical trial for the biparatopic CXCR2 nanobody was described as being for cancer instead of inflammation. This error has been corrected in the online version. (Source: Nature Reviews Drug Discovery)
Source: Nature Reviews Drug Discovery - September 1, 2017 Category: Drugs & Pharmacology Authors: Catherine J. Hutchings Markus Koglin William C. Olson Fiona H. Marshall Tags: Corrigendum Source Type: research
Cancer: Ironing it out
Nature Reviews Drug Discovery 16, 602 (2017).
doi:10.1038/nrd.2017.168
Author: Ulrike Harjes
Cancer cells with mesenchymal-like properties are more likely to become resistant to a wide range of therapies. A new study suggests that this mesenchymal-like state of cancer cells is vulnerable to inhibition of the lipid peroxidase pathway, leading to an iron-dependent form of cell death, (Source: Nature Reviews Drug Discovery)
Source: Nature Reviews Drug Discovery - September 1, 2017 Category: Drugs & Pharmacology Authors: Ulrike Harjes Tags: Research Highlight Source Type: research
Biotechnology: CRISPR – Cas becoming more human
Nature Reviews Drug Discovery 16, 601 (2017).
doi:10.1038/nrd.2017.167
Author: Kim Baumann
In the past few years, the CRISPR–Cas technology has been developed to precisely edit genomic DNA; so far, these approaches have been used mainly in cultured cells or in animal embryo models, but only a few studies have reported their use in human embryos. Ma (Source: Nature Reviews Drug Discovery)
Source: Nature Reviews Drug Discovery - September 1, 2017 Category: Drugs & Pharmacology Authors: Kim Baumann Tags: Research Highlight Source Type: research
Nigel Blackburn
Nature Reviews Drug Discovery 16, 596 (2017).
doi:10.1038/nrd.2017.172
In 2007, the charity Cancer Research UK (CRUK) launched its Clinical Development Partnerships (CDP) initiative to run trials of deprioritized anticancer candidates that still offered glimmers of promise. 10 years on, these reprioritization efforts have yielded mixed results. Despite generating some promising clinical data, none of their biopharma partners has as yet fully reprioritized any candidates. There is still hope for these drugs, although likely with new sponsors. In the case of an Aurora kinase inhibitor that was initially discovered by...
Source: Nature Reviews Drug Discovery - September 1, 2017 Category: Drugs & Pharmacology Tags: News and Analysis Source Type: research
Deal watch: IL-2 focus switches to stimulating Tregs
Nature Reviews Drug Discovery 16, 595 (2017).
doi:10.1038/nrd.2017.171
Author: Megan Cully
Recombinant interleukin-2 (IL-2) has been used since the early 1990s for the treatment of renal cell carcinoma and melanoma, as high-dose IL-2 has immune-stimulating properties. A spate of deals in 2017 — including Eli Lilly's acquisition of co-development rights to Nektar's NKTR-358, the acquisition (Source: Nature Reviews Drug Discovery)
Source: Nature Reviews Drug Discovery - September 1, 2017 Category: Drugs & Pharmacology Authors: Megan Cully Tags: News and Analysis Source Type: research
